A recombinant hepatitis B virus (HBV) expressing NanoLuc (NL) (HBV ⁄ NL) was produced by cotransfecting a plasmid containing a 1.2-fold HBV genome carrying the NL gene with a plasmid bearing a packaging-defective 1.2-fold HBV genome into a human hepatoma cell line, HepG2. We found that NL activity in HBV ⁄ NLinfected primary hepatocytes or sodium taurocholate cotransporting polypeptidetransduced human hepatocyte-derived cell lines increased linearly for several days after infection and was concordant with HBV RNA levels in the cells. Treatment of the virus-infected cells with HBV inhibitors reduced NL activity in a dosedependent manner. Detection of HBV ⁄ NL infection, monitored by NL activity, was highly sensitive and less expensive than detection using the conventional method to evaluate HBV infection. In addition, because we also studied host factors, this system is applicable not only for studying the HBV life cycle, but also for exploring agent(s) that regulate HBV proliferation.
A pproximately 370 million people worldwide are infected with hepatitis B virus (HBV). Antiviral therapies consisting of HBV polymerase inhibitors and ⁄ or interferon have been used in active chronic HBV carriers, (1) which may delay the progress of HBV-related diseases, but cannot cure HBV due to the persistence of HBV covalently closed circular DNA (cccDNA) in hepatocytes. A new strategy for HBV treatment depends on intensive characterization of the HBV life cycle through development of an efficient in vitro experimental system. However, the limited host range and liver tropism of HBV has hampered efforts to establish such a system. Human liver cells reflecting a primary hepatocyte nature are now available to monitor HBV infection and replication with comparably high efficiency. (2) Moreover, the discovery of sodium taurocholate cotransporting polypeptide (NTCP) as a prominent HBV receptor candidate enabled the establishment of HBVsusceptible cells derived from cell lines such as HepG2 and HuH7 by ectopic expression of NTCP. (3, 4) A foreign gene, such as a reporter or marker gene, is successfully incorporated into some viral genomes, including HIV-1 and hepatitis C virus without the loss of replication competency. (5) (6) (7) In contrast, the compact nature of the HBV genome and the presence of genomic cis-acting elements make it difficult to introduce a foreign gene without losing competency and replication efficiency. In constructing a recombinant HBV-reporter virus, cis-acting control regions such as the replication control region for pre-genomic RNA synthesis, packaging, and reverse transcription that locates from upstream of the X gene to the N-terminal region of the core gene need to remain intact. (8, 9) The size limitation of the genome restricts the length of foreign genes that often require replacement of virus DNA to accommodate the foreign gene; the destroyed function must be provided in trans to produce recombinant virus particles. Various methods have been explored to produce recombinant HBV. (10) (11) (12) (13) (14) (15) (16) (17) However, these recombinant HBVs are not designed to detect HBV infection with high sensitivity to analyze the HBV life cycle, nor for high-throughput screening of factors affecting HBV infection and replication.
Here, we constructed a reporter-based HBV to monitor infection with high sensitivity using the luciferase gene NanoLuc (NL) as a marker gene because NL is the shortest luciferase gene commercially available. Moreover, NL is approximately 100-fold brighter, with a linear increase of broad range greater than either firefly (Photinus pyralis) or Renilla reniformis luciferase. The use of NL or other relevant genes such as Gaussia luciferase would increase the sensitivity of HBV infection more than previously reported HBV recombinant viruses and authentic HBV.
Materials and Methods
Cells. HepG2 and HuH7 were cultured in DMEM (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U ⁄ mL penicillin, 100 lg ⁄ mL streptomycin, and 100 U ⁄ mL non-essential amino acids (Life Technologies) unless otherwise described. Primary human hepatocytes (PHH), PXB cells, isolated from urokinase-type plasminogen activator transgenic ⁄ SCID mice inoculated with PHH and HepaRG were purchased from PhoenixBio, Hiroshima, Japan and KAC, Kyoto, Japan respectively, and cultured under manufacturer's protocols. HepG2 ⁄ NTCP and HuH7 ⁄ NTCP cells are HepG2-and HuH7-derived cell lines transduced by pCAN-NTCP-myc and are susceptible to HBV infection.
Plasmids. We used a 1.2-fold HBV genome (isolate C_JPNAT, genotype C, accession number AB246345) cloned into the HindIII ⁄ EcoRI site of pUC19, termed pUC1.2x HBV. (18) The plasmid pUC1.2xHBV ⁄ NL was constructed by deleting 562 nt (219-782) from the first codon of the HBV preCore coding frame and then inserting the NL gene (513 nt) from pNL2.1 N1061 NLuc (Promega, Madison, WI, USA) by BD In-Fusion PCR cloning. Similarly, pUC1.2xHBV ⁄ NL+pol was constructed by deleting 141 nt (295-436) from the first codon of the HBV preCore coding frame and then inserting the NL gene at the 178 nt position from the first codon of preCore ⁄ Core by the In-Fusion method. The genome sizes of HBV ⁄ NL and HBV ⁄ NL+pol were 3302 and 3731 nt, respectively. Expression of NL was designed to start from its own initiation codon. HBV ⁄ NL(-Met) has mutations of all methionine residues converted to other amino acids or a terminator codon in the defective pol coding sequence of HBV ⁄ NL without affecting the amino acid sequence of S protein. The mutations are as follows: All ATGs at positions 330, 902, 1329,  1422, 1548, 1647, 1785, 1962, and 2142 in the polymerase  gene were converted to GTG, GTG, GTG, TTG, GTG, TTG,  TAG, TAG, and TAG, respectively. The plasmid pUC1.2xHBV-D, which produces all HBV proteins, has two mutations in the encapsidation signal (CTGTGCC to CTATGTC), and, thus, does not produce progeny virus. The plasmid pUC1.2xHBV-D ⁄ MHD is mutated in the catalytic domain, MDD, of HBV-D pol to MHD. The plasmid pCAN-NTCP-myc was constructed by inserting human NTCP cDNA tagged with myc at the 3 0 -end into pCAN. The plasmid pX330 was obtained from Addgene (plasmid 42230; Cambridge, MA, USA). Oligonucleotides designed for each target site were inserted into the BbsI site of pX330.
Production of recombinant virus. The pUC1.2xHBV ⁄ NL, pUC1.2xHBV ⁄ NL+pol, or pUC1.2xHBV ⁄ NL(-Met) plasmids were cotransfected with pUCxHBV-D into HepG2 or HuH7 cells using Lipofectamine 3000 (Life Technologies). Medium was harvested 3 or 4 days after transfection and the virus fraction prepared by precipitation with 13% PEG6000 (SigmaAldrich, St. Louis, MO, USA) containing 0.75 M NaCl. Virus was further purified by precipitation through 20% sucrose in TNE buffer (10 mM Tris [pH 7.6], 50 mM NaCl, 1 mM EDTA) at 100 000 g for 3 h. Virus was then suspended in Opti-MEM (Life Technologies) and stored at À80°C until use.
Infection and assay of NL activity. Cells were infected with virus at a genome equivalent of 10-100 in the presence of 4% PEG8000 and 2% DMSO overnight. Activity of NL and cell viability were then measured using the NL Luciferase Assay Kit 0 (reverse) for NL. Cesium chloride density equilibrated centrifugation. The virus fraction was centrifuged at 150 000 g for 50 h on a CsCl gradient (in 10 mM Tris [pH 7.6], 150 mM NaCl, and 1 mM EDTA) from 1.1 to 1.6 g ⁄ mL. An aliquot from the top of the gradient tube was collected for further analysis.
Small interfering RNA transfection. The siRNA was transfected using Lipofectamine RNAiMAX Reagent (Life Technologies) according to the manufacturer's protocol. The duplex nucleotides of siRNA specific to the mRNA and the Mission siRNA Universal Negative control were purchased from SigmaAldrich (St. Louis, MO, USA). Sequences of siRNAs for hepatocyte nuclear factor 4 alpha (HNF4A) and NTCP were: HNF4A, 5 0 -CGCUACUGCAGGCUCAAGATT-3 0 (sense) and 5 0 -UCUUGAGCCUGCAGUAGCGTT-3 0 (antisense); and NTCP 5 0 -CAAGGCUCACUUAUGGAAGTT-3 0 (sense), and 5 0 -CUUCCAUAAGUGAGCCUUGTT-3 0 (antisense). Screening of host factors by siRNA. siGENOME containing siRNAs targeting 18 236 human genes was purchased from Dharmacon GE Healthcare (Little Chalfont, Buckinghamshire HP7 9NA, UK). HepG2 ⁄ NTCP, HuH7 ⁄ NTCP, or PXB cells were transfected with 4 pmol siRNA using Lipofectamine , and pUC1.2xHBV-D (c) were centrifuged at 150 000 g for 50 h in a CsCl gradient. An aliquot from the top of the centrifuged tube was collected. Hepatitis B surface antigen (HBsAg; blue) in 10% of each aliquot was quantified by automated ELISA. The amount of NL DNA (dotted blue line) (b) and HBV DNA (dotted black line) (a, c) in 10% of each fraction was measured by quantitative PCR using a primer set for the NL gene and HBV DNA, respectively. Infectivity of 25% of each fraction in a and b was assayed by infecting 2 9 10 5 HepG2 ⁄ NTCP cells and measuring HBV DNA by quantitative PCR for wild HBV (green) (a) and NL activity for HBV ⁄ NL (red) (b) of 10% of the total cell lysate. Pink dots denote buoyant density. Southern blot analysis of each fraction was carried out by probing with digoxigenin-labeled HBV DNA.
RNAiMAX in 96-well plates. At 48 h following transfection, cells were infected with HBV ⁄ NL in the presence of 2% DMSO and 4% PEG8000. At 96 h following infection, cells were lysed and NL activity and cell viability were measured.
Gene knockout. The clustered regularly interspaced short palindromic repeats (CRISPR) ⁄ Cas9-based gene knockout (KO) plasmid was generated using annealed oligonucleotides and cloned into pX330. HuH7 ⁄ NTCP or HepG2 ⁄ NTCP cells were then transfected with each targeting plasmid derived from the pX330 plasmid along with a puromycin-resistant plasmid. After transfection, cells were treated with 1.5 lg ⁄ mL puromycin and single cell colonies were collected. The KO of each gene was confirmed by Western blotting or sequencing of the target region.
Results
Construction of HBV and NL plasmids. We inserted the NL gene downstream of the HBV replication control region as described in "Materials and Methods". If the size of the HBV genome is 0.7 kb over the original genome size, (15) replication decreases, therefore HBV DNA similar to the size of the NL gene was deleted from the 3 0 -terminal region of the core gene to the 5 0 -terminal region of the polymerase gene to make pUC1.2xHBV ⁄ NL. Thus, pUC1.2xHBV ⁄ NL lacked 562 nt of HBV DNA from the 3 0 -terminal half of the core coding region to the 5 0 -coding region of the polymerase coding region, resulting in non-functional preCore ⁄ Core and polymerase proteins. However, pUC1.2xHBV ⁄ NL+pol lacked part of the core coding sequence but retained the entire polymerase coding sequence. The deletion of 141 nt from the core coding sequence made this construct 3731 nt long, which is more than 450 nt longer than the original HBV genome. In pUC1.2xHBV ⁄ NL(-Met), the internal methionine codons in the defective pol coding region of pUC1.2xHBV ⁄ NL were mutated to prevent the possible translation of any polymerase-derived peptide that may interfere with HBV replication. These mutations were designed so as not to alter the amino acid sequence of hepatitis B surface antigen. The expression of the NL gene was expected to be under the same regulatory mechanism of authentic preCore ⁄ Core because transcriptional control elements of the HBV genome remained intact. A schema of these genomic structures is shown in FigFig 7 HuH7 ⁄ NTCP cells infected with approximately 1000 equivalent copies of wild HBV or HBV ⁄ NL DNA per cell. The cccDNA fraction was prepared by the method previously reported. (29) Digestion with XbaI, which has a single cutting site in the genomes, converts the cccDNA to a single linear form. ure 1(a). HBV ⁄ NL+pol and HBV ⁄ NL(-Met) were also examined for infectivity by assaying NL activity in the infected cells (Fig. 1B) . HBV ⁄ NL+pol had less than one-tenth the NL activity of HBV ⁄ NL. Production of HBV ⁄ NL+pol as measured by qPCR for HBV DNA in the culture medium of pUC1.2xHBV ⁄ NL+pol-transfected HepG2 cells was less than one-tenth that of HBV ⁄ NL (data not shown). It is likely that the genome size limitation for packaging was exceeded, resulting in less efficient virus production. (15) HBV ⁄ NL(-Met) had the same NL activity levels as HBV ⁄ NL, and virus production, as measured by HBV DNA from the cells transfected with pUC1.2xHBV ⁄ NL(-Met), was nearly the same as that from the pUC1.2xHBV ⁄ NL-transfected cells (data not shown). These data indicate that production of peptides from internal methionine residues in the polymerase reading frame does not interfere with recombinant virus production or influence NL activity.
Production and characterization of recombinant viruses. Recombinant viruses were produced from the plasmids described above and then characterized. HepG2 or HuH7 cells were transfected with the reporter plasmid, pUC1.2xHBV ⁄ NL, pUC1.2xHBV ⁄ NL+pol, or pUC1.2xHBV ⁄ NL(-Met) together with the plasmid pUC1.2xHBV-D. HBV-D is a replication-defective virus genome that produces the complementary proteins required for recombinant virus production. As a positive control, pUC1.2xHBV, which produces wild-type HBV, was also transfected. Culture medium from cells was harvested 4 days after transfection and the virus was partially purified as described in "Materials and Methods". Production of HBV and its derivatives was then analyzed by CsCl density equilibrated centrifugation (Fig. 2) . The medium from the cells transfected with the plasmid producing wild-type HBV yielded an HBV DNA profile with two peaks, consistent with the Southern blot data (Fig. 2a) . Upon analysis, fractions 4-7 were found to be infectious, with the highest infectivity from fraction 6. Fraction 6 had a density of 1.23 g ⁄ mL and coincided with the lighter peak of the HBV DNA profile. The DNA peak with the high density appeared to be derived from the unenveloped capsid particles of HBV, as described by others. (16) A profile of HBV ⁄ NL was observed through analysis of the enriched virus fraction of pUC1.2xHBV ⁄ NL plus pUC1.2xHBV-D-transfected cell culture medium. After infection of each fraction to HepG2 ⁄ NTCP, NL activity was detectable only in fractions 4-7, peaking at fraction 6 with the highest buoyant density similar to wild-type HBV (Fig. 2b) , indicating that the infectious HBV ⁄ NL was produced. We also observed two peaks by DNA titration analyzed by quantitative PCR (qPCR) using primers for the NL gene as well as Southern blot using HBV DNA as a probe (Fig. 2b) . As no peak of HBV DNA was observed in culture medium from the cells transfected with pUC1.2xHBV-D, virus-like particles were not produced from the plasmid bearing HBV-D DNA (Fig. 2c) . Moreover, no virus with NL activity was produced from culture medium of cells transfected with pUC1.2xHBV ⁄ NL and pUC1.2xHBV-D ⁄ MHD, both of which lack pol activity (data not shown). This observation strongly suggests that generation of wild HBV by genetic conversion between these plasmids is less likely.
Activity of NL in HBV ⁄ NL-infected cells reflects HBV RNA levels.
In order to analyze the HBV life cycle as well as to screen for factors affecting the HBV life cycle, we analyzed how faithfully the NL activity of HBV ⁄ NL reflected the authentic HBV life cycle in infected cells and how sensitively NL activity could evaluate the HBV life cycle. We carried out a time course of NL activity in HBV ⁄ NL-infected PXB cells, a PHH susceptible to HBV infection (Fig. 3) . (19) The HBV DNA and RNA levels increased in a time-dependent manner in PXB cells following HBV infection (Fig. 3a) ; NL activity became detectable 3 days after HBV ⁄ NL infection and increased for 6 days along with HBV RNA levels (Fig. 3b) . Although HBV DNA was detectable throughout these time points, it stayed unchanged at a low level (Fig. 3b) . Similar levels of NL activity and RNA were observed in HBV ⁄ NL-infected HepG2 ⁄ NTCP cells (Fig. 3c) . A slight decline in both markers 9 or 13 days after the infection of PXB or HepG2 ⁄ NTCP cells, respectively, coincided with cell loss (Fig. 3b,c and data not shown) . These data suggest that NL activity was a consequence of transcription from the HBV recombinant genome in cells after infection. Hepatitis B virus transcription begins on virus cccDNA, (9) therefore NL expression indicates the completion of an early event in the HBV life cycle, from entry to transcription ⁄ translation through cccDNA formation. Consistently low levels of HBV DNA in PXB cells from 3 days after infection suggest that neither de novo synthesis of the relaxed circular form of HBV DNA, nor the amplification process of cccDNA occurred due to the lack of active polymerase from the recombinant virus (Fig. 3b,c) . However, cccDNA in HBV ⁄ NL-infected HuH7 ⁄ NTCP cells was detectable as early as 4 days following infection (Fig. 3d) . This cccDNA could be the product converted from the relaxed circular form of HBV DNA by HBV polymerase residing in the virus particles that penetrated the cells.
We then examined the effect of HBV inhibitors, including human hepatitis B immunoglobulin (HBIG), entecavir, and IFNb on NL activity in HBV ⁄ NL-infected cells. We first examined the effect of these inhibitors on the infection and replication of wild-type HBV. PXB cells were infected with HBV in the presence of each inhibitor for 7 days and the level of HBV DNA and RNA was measured (Fig. 4a,b) . Entecavir, an HBV polymerase inhibitor, and IFNb suppressed HBV DNA levels by <15% at 0.1 lM and 250 IU ⁄ mL, respectively; HBIG suppressed HBV DNA levels by <10% at 1 U ⁄ mL. Both IFNb and HBIG, at higher concentrations of 750 IU ⁄ mL and 5 U ⁄ mL, respectively, decreased HBV DNA even further (Fig. 4a) . We simultaneously determined the effect of these inhibitors on HBV RNA levels and found that RNA levels in the IFNb-and HBIG-treated cells was reduced to <10% (Fig. 4b) , whereas entecavir reduced RNA levels to 30% (Fig. 4b) . Next, we analyzed NL activity and HBV RNA and DNA levels in PXB, HepG2 ⁄ NTCP, and HepaRG cells infected with HBV ⁄ NL in the presence of the inhibitors (Figs 4c,d,S1 ). In these cells, entecavir, at a dose of 0.1 lM, suppressed NL activity by 30% whereas IFNb and HBIG decreased NL activity by <10% at 250 IU ⁄ mL and 1 U ⁄ mL, respectively, 7 days after infection. The HBV RNA levels correlated well with NL activity (Figs 4d,S1 ), indicating that NL activity reflects HBV RNA levels.
Screening of host factors affecting early stages of the HBV life cycle. We applied the HBV ⁄ NL system to host factor screening by sequence-specific RNAi gene silencing. We determined the feasibility of this system to evaluate host factors involved in HBV proliferation by targeting HNF4A and NTCP, which are important for HBV replication and infection, respectively. Both HNF4A and NTCP were knocked down in HepG2 ⁄ NTCP cells by specific siRNAs by 50% or less (Fig. S2a) . The cells were then infected with HBV ⁄ NL to evaluate NL activity 5 days after infection. We found that NL activity was reduced to levels half that of the control cells (Fig. S2b) , indicating that host factors influencing HBV infection ⁄ replication also affect NL activity of HBV ⁄ NL.
Next, siRNA libraries for 18 236 genes were used to determine host factors that regulate the HBV life cycle. Candidate genes with more than a 40% reduction or 200% activation of NL activity in HepG2 ⁄ NTCP cells were further analyzed by a second screening in HuH7 ⁄ NTCP cells. Of these, genes with more than a 35% reduction or 200% activation with <20% non-toxicity to cells were included (Table 1) . These genes were significantly expressed in HepG2, HuH7, and PHH cells in the presence of 2% DMSO as evaluated by microarray (data not shown). Consistent with previous reports, (21) (22) (23) (24) we also identified host factors such as CEBPA, BclxL, KPNB1, and CHORDC1. We then randomly chose several of these genes (CD2BP2, PON2, FBP1, TRAF2, GORASP2, MCL1, KAT5, and NPM3) and established KO cells of each by the CRISPR-Cas9 system (Fig. 5a ) to further evaluate their role in HBV infection and replication. Infection of HBV ⁄ NL in MCL1-, PON2-, TRAF2-, or GORASP2-KO cells clearly reduced NL activity (Fig. 5b) . As expected, HBV ⁄ NL replication was significantly enhanced by KO of KAT5 or NPM3. Infectivity of authentic HBV, as measured by virus RNA levels, correlated well with HBV ⁄ NL results (Fig. 5c) . The difference in HBV infectivity between cell types may reflect the degree to which the knocked-out gene contributed to HBV infection ⁄ replication. These results clearly indicate the usefulness of the HBV ⁄ NL system to explore factors that regulate the HBV life cycle. 
Discussion
We developed an HBV reporter system to analyze virus replication and screen anti-HBV agents with a simple, high-efficiency procedure. We produced a recombinant virus, HBV ⁄ NL, that mimics early events of the HBV life cycle. The HBV ⁄ NL virus had the same buoyant density as authentic HBV and showed NL activity following infection into various HBV-susceptible cells (Figs 1-3) . Through analysis of HBV DNA and RNA as well as NL activity in HBV ⁄ NL-infected cells, we found that NL activity reflected RNA levels. Both NL activity and HBV RNA levels increased linearly for at least 6 days after infection, whereas HBV DNA levels remained low, likely due to the non-functional polymerase in HBV ⁄ NL. The HBV DNA that was detected by PCR specific for cccDNA was likely derived from the incorporated virus after infection (data not shown) as Southern blot analysis showed cccDNA was present as early as 4 days following infection (Fig. 3d) . Hepatitis B virus inhibitors, such as HBIG, entecavir, and IFNb, suppressed NL activity in a dose-dependent manner (Figs 4,S1 ). Suppression of NL activity by HBIG was likely an inhibition of virus entry into cells, whereas suppression of NL activity by entecavir or IFNb was likely an inhibition of HBV reverse transcription or virus replication, respectively, as previously described. (25) (26) (27) Inhibition of NL activity by entecavir in cells infected with HBV ⁄ NL that does not encode functional pol is likely to be by inhibition of polymerase that resides in the penetrated virus and is required for conversion from virion-associated HBV DNA to the ccc form. Inhibition of NL activity by these reagents correlated with HBV RNA suppression (Fig. 4) , indicating that the NL activity of HBV ⁄ NL-infected cells reflects early events of the HBV life cycle.
Evaluation of HBV infection using the HBV ⁄ NL system is simple and more sensitive than quantitating HBV DNA or RNA by qPCR or qRT-PCR. Furthermore, this system could be used for large-scale screening of agents and host factors that regulate the HBV life cycle. Taking advantage of the high sensitivity of the HBV ⁄ NL system to evaluate early stages of HBV infection and replication, we searched for host factors that affect the HBV life cycle using siRNA targeting 18 236 human genes. Approximately 50 genes that affected the NL activity of HBV ⁄ NL were identified, some of which have been previously identified to regulate the HBV life cycle (Table 1) . Those HBV ⁄ NL-infected cells with siRNA knocked-out genes CD2BP2, PON2, FBP1, TRAF2, GORASP2, MCL1, KAT5, or NPM3 (Table 1) produced similar results to the infectivity assay. However, there was no effect on HBV replication in CD2BP2 or FBP1 KO cells; this may be due to false negatives and positives that occur frequently in siRNA screening. (28) Taken together, the results of the HBV ⁄ NL infectivity assay, as measured by NL activity, and the infectivity of authentic HBV, as assayed by virus RNA levels, correlated well (Fig. 5) .
In summary, we successfully produced a recombinant HBV expressing NL for evaluation of the HBV early life cycle, from entry to transcription. We also showed the utility of this system by identifying cellular factors that affect HBV infection and replication. (9) Due to the high sensitivity of our assay in characterizing infection, this system would be applicable for identifying low molecular weight agents that affect HBV proliferation and antibodies that inhibit HBV infection, as well as for exploring host factors affecting HBV when combined with siRNA techniques.
